BACKGROUND: Heartland virus (HRTV) was first described as a human pathogen in 2012. From 2013 to 2017, the Centers for Disease Control and Prevention (CDC) implemented a national protocol to evaluate patients for HRTV disease, better define its geographic distribution, epidemiology, and clinical characteristics, and develop diagnostic assays for this novel virus. METHODS: Individuals aged ≥12 years whose clinicians contacted state health departments or the CDC about testing for HRTV infections were screened for recent onset of fever with leukopenia and thrombocytopenia. A questionnaire was administered to collect data on demographics, risk factors, and signs and symptoms; blood samples were tested for the presence of HRTV RNA and neutralizing antibodies. RESULTS: Of 85 individuals enrolled and tested, 16 (19%) had evidence of acute HRTV infection, 1 (1%) had past infection, and 68 (80%) had no infection. Patients with acute HRTV disease were residents of 7 states, 12 (75%) were male, and the median age (range) was 71 (43-80) years. Illness onset occurred from April to September. The majority reported fatigue, anorexia, nausea, headache, confusion, arthralgia, or myalgia. Fourteen (88%) cases were hospitalized; 2 (13%) died. Fourteen (88%) participants reported finding a tick on themselves in the 2 weeks before illness onset. HRTV-infected individuals were significantly older (P < .001) and more likely to report an attached tick (P = .03) than uninfected individuals. CONCLUSIONS: Health care providers should consider HRTV disease testing in patients with an acute febrile illness with either leukopenia or thrombocytopenia not explained by another condition or who were suspected to have a tickborne disease but did not improve following appropriate treatment. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.
BACKGROUND: Heartland virus (HRTV) was first described as a human pathogen in 2012. From 2013 to 2017, the Centers for Disease Control and Prevention (CDC) implemented a national protocol to evaluate patients for HRTV disease, better define its geographic distribution, epidemiology, and clinical characteristics, and develop diagnostic assays for this novel virus. METHODS: Individuals aged ≥12 years whose clinicians contacted state health departments or the CDC about testing for HRTV infections were screened for recent onset of fever with leukopenia and thrombocytopenia. A questionnaire was administered to collect data on demographics, risk factors, and signs and symptoms; blood samples were tested for the presence of HRTV RNA and neutralizing antibodies. RESULTS: Of 85 individuals enrolled and tested, 16 (19%) had evidence of acute HRTV infection, 1 (1%) had past infection, and 68 (80%) had no infection. Patients with acute HRTV disease were residents of 7 states, 12 (75%) were male, and the median age (range) was 71 (43-80) years. Illness onset occurred from April to September. The majority reported fatigue, anorexia, nausea, headache, confusion, arthralgia, or myalgia. Fourteen (88%) cases were hospitalized; 2 (13%) died. Fourteen (88%) participants reported finding a tick on themselves in the 2 weeks before illness onset. HRTV-infected individuals were significantly older (P < .001) and more likely to report an attached tick (P = .03) than uninfected individuals. CONCLUSIONS: Health care providers should consider HRTV disease testing in patients with an acute febrile illness with either leukopenia or thrombocytopenia not explained by another condition or who were suspected to have a tickborne disease but did not improve following appropriate treatment. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.
Authors: Elisabeth R Krow-Lucal; Nicole P Lindsey; Marc Fischer; Susan L Hills Journal: Vector Borne Zoonotic Dis Date: 2018-03-13 Impact factor: 2.133
Authors: Kristen Nichols Heitman; F Scott Dahlgren; Naomi A Drexler; Robert F Massung; Casey Barton Behravesh Journal: Am J Trop Med Hyg Date: 2015-11-30 Impact factor: 2.345
Authors: Laura K McMullan; Scott M Folk; Aubree J Kelly; Adam MacNeil; Cynthia S Goldsmith; Maureen G Metcalfe; Brigid C Batten; César G Albariño; Sherif R Zaki; Pierre E Rollin; William L Nicholson; Stuart T Nichol Journal: N Engl J Med Date: 2012-08-30 Impact factor: 91.245
Authors: Marvin S Godsey; Harry M Savage; Kristen L Burkhalter; Angela M Bosco-Lauth; Mark J Delorey Journal: J Med Entomol Date: 2016-09-01 Impact factor: 2.278
Authors: Monica M Brackney; Anthony A Marfin; J Erin Staples; Lorann Stallones; Thomas Keefe; William C Black; Grant L Campbell Journal: Vector Borne Zoonotic Dis Date: 2010-05 Impact factor: 2.133